Novo Nordisk trims outlook
Digest more
Novo Nordisk’s oral semaglutide 25 mg achieved up to 16.6% weight loss in a landmark study, rivaling injectable Wegovy. The ...
Novo Nordisk reports Wegovy users lost 21% body weight and saw improved heart health markers, as EMA and FDA reviews near for ...
50m
Why Novo Nordisk (CPSE:NOVO B) Is Down 10.1% After Lower Guidance and Restructuring Amid Wegovy Data
On November 5, 2025, Novo Nordisk reported lower full-year sales and profit guidance following third-quarter results amid slowing growth in its obesity and diabetes businesses, while presenting new ...
Pedersen, Maggie Fick and Bhanvi Satija COPENHAGEN (Reuters) -Wegovy-maker Novo Nordisk trimmed its full-year profit and ...
Novo Nordisk’s oral therapy Wegovy (semaglutide) reduced cardiovascular risk factors in the Phase III OASIS 4 trial. Being ...
Obesity medicines coverage in U.S. Medicare Part D via a pilot programme, starting during 2026Introduction of lower prices ...
Novo Nordisk said on Wednesday it had agreed a price under the U.S. Medicare scheme for semaglutide, the active ingredient in ...
Novo Nordisk executive Gordon Findlay fainted in the Oval Office on Thursday during President Trump’s announcement of a new ...
Telehealth company Hims & Hers Health Inc. said late Monday it is in “active discussions” with Denmark’s Novo Nordisk A/S to ...
The ultimate defense in our industry is in innovation,” Karsten Munk Knudsen told Fortune in an exclusive interview.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback